Related Experiment Videos
[Long-term performance of mitral valve bioprosthesis]
L K von Segesser1, R Enz, E Bauer
1Klinik für Herzgefässchirurgie, Universitätsspital Zürich.
Schweizerische Medizinische Wochenschrift
|July 28, 1990
Summary
Long-term mitral bioprosthesis implantation shows significant risks. After 11 years, only 35% of patients remain free of complications like valve deterioration or death, with 50% requiring reoperation.
Area of Science:
- Cardiovascular Surgery
- Biomaterials Science
- Clinical Outcomes Research
Context:
- Mitral valve disease necessitates prosthetic replacement.
- Bioprosthetic valves offer an alternative to mechanical options.
- Long-term durability and complication rates are critical for patient management.
Purpose:
- To evaluate the long-term clinical performance and complication rates of mitral bioprostheses.
- To provide actuarial data on survival, thromboembolism, endocarditis, valve deterioration, and reoperation.
- To inform clinical decision-making regarding mitral valve repair versus replacement.
Summary:
- A 13-year study analyzed 250 patients receiving mitral bioprostheses, with a mean follow-up of 71 months.
- Key complications included late mortality (2.0%/patient-year), thromboembolism (1.4%/patient-year), endocarditis (1.0%/patient-year), and structural valve deterioration (3.0%/patient-year).
- Reoperation rates were 3.4%/patient-year, with 11-year actuarial freedom from complications at 35% and freedom from reoperation at 50%.
Impact:
- Findings highlight the substantial long-term risks associated with mitral bioprostheses, particularly structural valve deterioration and the need for reoperation.
- The data underscores the importance of patient selection and ongoing monitoring for complications.
- This research contributes to the understanding of bioprosthetic valve longevity and informs future device development and clinical guidelines.